SK BIOPHARMACEUTICALS CO., LTD.

The present disclosure provides a compound of a specific chemical structure, an optical isomer, stereoisomer, isotopic variant, hydrate or solvate thereof, or a pharmaceutically acceptable salt thereof, which has excellent activity in terms of degradation of SHP2 protein. The present disclosure also provides a composition comprising such a compound, an optical isomer, stereoisomer, isotopic variant, hydrate or solvate thereof, or a pharmaceutically acceptable salt thereof. The present disclosure also provides medical uses of a composition comprising the compound according to the present disclosure, an optical isomer, stereoisomer, isotopic variant, hydrate or solvate thereof, or a pharmaceutically acceptable salt thereof, for the treatment or prevention of SHP2-associated diseases (for example, cancer). The present disclosure also provides a method for treating or preventing SHP2-associated diseases (for example, cancer), the method comprising administering, to an individual in need of treatment, an effective amount of a composition comprising the compound according to the present disclosure, an optical isomer, stereoisomer, isotopic variant, hydrate or solvate thereof, or a pharmaceutically acceptable salt thereof.

The present disclosure pertains to a pharmaceutical combination for treating and/or preventing cancer and a method and use thereof. Specifically, the present disclosure involves a method for inhibiting tumor growth by combining a substance inhibitory of the activity of protein arginine methyltransferase and a drug that is similar to or different from the substance in terms of mechanism, and/or a pharmaceutical combination useful for reducing tumor volume using same. Particularly, a pharmaceutical combination comprising a PRMT5 inhibitor and a DNA damage-inducing substance is provided.

The present invention relates to a pharmaceutical composition for preventing or treating trigeminal neuralgia, the pharmaceutical composition comprising: a carbamate compound of chemical formula 1 or a pharmaceutically acceptable salt thereof, a solvate or a hydrate; and a pharmaceutically acceptable carrier. The pharmaceutical composition, according to the present invention, may enable the efficient prevention or treatment of trigeminal neuralgia.

The present disclosure provides combination therapy using [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate (cenobamate) and one or more antiepileptic drugs for the prevention or treatment of a neurological disorder such as epilepsy.

The present invention relates to an oral pharmaceutical composition comprising a carbamate compound of chemical formula 1, an isomer thereof, or a pharmaceutically acceptable salt, solvate, or hydrate thereof as an active ingredient, and a preparation method therefor.

The invention is directed to a method of treating attention-deficit/hyperactivity disorder (ADHD) in a subject, comprising administering a therapeutically effective amount of a carbamoyl compound, or pharmaceutically acceptable salt thereof.

The present invention relates to a use to be used for the purpose of preventing, alleviating or treating diabetic peripheral neuropathy or chemotherapy-induced peripheral neuropathy by administering a pharmaceutical composition containing a carbamate compound of chemical formula 1.

The present invention relates to an orally disintegrated tablet and a method for producing same, the tablet containing a carbamate compound of chemical formula 1, an isomer thereof, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof, as an active ingredient.

The present invention relates to use of a carbamate compound of Formula 2 for the purpose of preventing, alleviating or treating diabetic peripheral neuropathy or chemotherapy-induced peripheral neuropathy by administering a pharmaceutical composition comprising a carbamate compound of Formula 2.

The present invention relates to a newly identified solvate form of (R)-2-amino-3-phenylpropyl carbamate (APC) hydrochloride, a method of preparing APC hydrochloride, and methods of using the same to treat disorders. The invention further relates to methods of producing APC hydrochloride with increased purity.